Please log in to determine if you are eligible to purchase PT Programs.
DRUG MONITORING FOR PAIN MANAGEMENT - DMPM
DMPM
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Analyte Challenges/Shipment Number of Shipments
See drug listing 3 Two shipments per year

Program Information

  • Three 40.0‑mL urine specimens
  • For laboratories offering qualitative, confirmatory, and/or quantitative urine drug analysis for pain management
  • Includes clinical cases and questions along with detailed descriptions of how to interpret test results

Shipping Schedule

  • Shipment A: February 11
  • Shipment B: August 12

Challenges will include a mix of drugs from the list below.
Amphetamine group
6-acetylmorphine (6-AM)
7-aminoclonazepam
Alpha-hydroxyalprazolam
Alprazolam
Amphetamine
Barbiturate group
Benzodiazepine group
Benzoylecgonine
Buprenorphine
Buprenorphine and/or metabolites
Butalbital
Cannabinoids
Carisoprodol
Carisoprodol and/or metabolites
Clonazepam
Cocaine
Cocaine and/or metabolites

Codeine
Delta-9-THC-COOH
Diazepam
Fentanyl
Fentanyl and/or metabolites
Gabapentin
Hydrocodone
Hydromorphone
l-Amphetamine
l-Methamphetamine
Lorazepam
Lorazepam glucuronide
Meperidine
Meperidine and/or metabolites
Meprobamate
Methadone
Methadone metabolite (EDDP)
Methamphetamine
Methylenedioxyamphetamine (MDA)
Methylenedioxymethamphetamine (MDMA)


Morphine
N-desmethyltramadol
Norbuprenorphine
Nordiazepam
Norfentanyl
Normeperidine
Noroxycodone
Noroxymorphone
Norpropoxyphene
O-desmethyltramadol
Opiate group
Oxazepam
Oxycodone
Oxymorphone
Phenobarbital
Pregabalin

Propoxyphene and/or metabolites
Tapentadol
Tapentadol-0-sulfate
Temazepam
Tramadol
Tramadol and/or metabolites